{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T12:01:06Z","timestamp":1774440066480,"version":"3.50.1"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Atherosclerotic cardiovascular diseases (ASCVD) and dyslipidemia are associated to a higher risk of cardiovascular events, mortality, use of healthcare resources and costs. In Spain, the evidence about the administration of lipid-lowering treatments in clinical practice, and their clinical effectiveness in patients with ASCVD and hypercholesterolemia and patients with FH is scarce. Therefore, a multidisciplinary working group of cardiologists, family physicians, internal medicine specialists and neurologists was gathered for the Reality study. The aim of this study is to describe the demographic and clinical characteristics, comorbidities, and concomitant medication of patients with ASCVD and hypercholesterolemia and of patients with familial hypercholesterolemia (FH). The use of healthcare resources and costs associated to the management of these diseases after their diagnosis were also considered.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is an observational and retrospective study, based on the BIG-PAC<jats:sup>\u00ae<\/jats:sup> database, which includes the electronic medical registries (EMRs) of 1.8 million people from 7 Autonomous Communities in Spain (including public primary care centers and hospitals). The study includes patients who had a new or recurrent episode of ASCVD during the recruitment period (from 01\/01\/2017 to 31\/12\/2018). The index date will be defined as the date of the ASCVD event, and the follow-up period will be 24 months. According to their first diagnosis in the database, patients will be classified as ASCVD (5 groups: stable\/unstable angina, acute myocardial infarction, ischemic stroke, transient ischemic attack, and peripheral arterial disease) or FH.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This study aims to analyze the treatment patterns and use of healthcare resources of ASCVD and FH in Spain. The prevalence of these disorders will also be estimated. Due to the high morbidity and mortality associated with these diseases, it is expected that our study will provide useful information for healthcare systems and decision makers to improve the management of these disabling diseases.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.966049","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T05:02:42Z","timestamp":1659589362000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment patterns and use of healthcare resources of patients with atherosclerotic cardiovascular disease and hypercholesterolemia and patients with familial hypercholesterolemia in Spain: Protocol of the Reality study"],"prefix":"10.3389","volume":"9","author":[{"given":"Vivencio","family":"Barrios","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar","family":"Castellanos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raquel","family":"Campuzano Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge Francisco","family":"G\u00f3mez Cerezo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Egocheaga Cabello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 M.","family":"G\u00e1mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ic\u00edar","family":"Mart\u00ednez L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"Mostaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Morant Talamante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Parrondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aram","family":"Sicras Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00e9s","family":"P\u00e9rez Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoni","family":"Sicras-Mainar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Pallar\u00e9s-Carratal\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e596","DOI":"10.1016\/j.jacc.2019.03.010","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation."},{"key":"B2","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.arteri.2014.12.003","article-title":"Diabetes mellitus and cardiovascular risk: Working group recommendations of Diabetes and Cardiovascular Disease of the Spanish Society of Diabetes (SED, 2015)","volume":"27","author":"Arrieta","year":"2015","journal-title":"Clin Investig Arterioscler."},{"key":"B3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e0210988","DOI":"10.1371\/journal.pone.0210988","article-title":"Effect of evidence-based therapy for secondary prevention of cardiovascular disease: systematic review and meta-analysis","volume":"14","author":"Ma","year":"2019","journal-title":"PLoS ONE."},{"key":"B5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1001\/jama.2017.3303","article-title":"Behavioral counseling to promote a healthful diet and physical activity for cardiovascular disease prevention in adults without known cardiovascular disease risk factors: updated evidence report and systematic review for the US preventive services task force","volume":"318","author":"Patnode","year":"2017","journal-title":"JAMA."},{"key":"B6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s11886-019-1175-z","article-title":"Optimizing dyslipidemia management for the prevention of cardiovascular disease: a focus on risk assessment and therapeutic options","volume":"21","author":"Berman","year":"2019","journal-title":"Curr Cardiol Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1111\/jgs.16353","article-title":"The prevention of cardiovascular disease in older adults","volume":"68","author":"Coll","year":"2020","journal-title":"J Am Geriatr Soc."},{"key":"B8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11886-019-1159-z","article-title":"New insights in the control of low-density lipoprotein cholesterol to prevent cardiovascular disease","volume":"21","author":"Katzmann","year":"2019","journal-title":"Curr Cardiol Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.atherosclerosis.2019.07.008","article-title":"Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: pooled analysis of nine ODYSSEY trials of alirocumab versus control","volume":"288","author":"Vallejo-Vaz","year":"2019","journal-title":"Atherosclerosis."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists' (CTT)","year":"2010","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.artere.2019.05.001","article-title":"new rational approach to reach LDL-cholesterol concentration objectives after an acute coronary syndrome","volume":"31","author":"Ribas","year":"2019","journal-title":"Clin Investig Arterioscler."},{"key":"B12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.arteri.2015.02.004","article-title":"Update of planning tables of cholesterol-lowering therapy orientated to achieve LDL therapeutic targets","volume":"27","author":"Masana","year":"2015","journal-title":"Clin Investig Arterioscler."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","article-title":"2017 Focused Update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the american college of cardiology task force on expert consensus decision pathways","volume":"70","author":"Lloyd-Jones","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1177\/2047487318825350","article-title":"Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry","volume":"26","author":"Kotseva","year":"2019","journal-title":"Eur J Prev Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-Wide Cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/14779072.2020.1717335","article-title":"Improving adherence to cardiovascular guidelines: realistic transition from paper to patient","volume":"18","author":"Mahtta","year":"2020","journal-title":"Expert Rev Cardiovasc Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"4513","DOI":"10.3390\/ijms20184513","article-title":"Discontinued drugs for the treatment of cardiovascular disease from 2016 to 2018","volume":"20","author":"Li","year":"2019","journal-title":"Int J Mol Sci."},{"key":"B18","unstructured":"Big-Pac2021"},{"key":"B19","unstructured":"Ley Org\u00e1nica 3\/2018, de 5 de diciembre, de Protecci\u00f3n de Datos Personales y garant\u00eda de los derechos digitales2018"},{"key":"B20","doi-asserted-by":"publisher","first-page":"S734","DOI":"10.1016\/j.jval.2019.09.1764","article-title":"PMU146 Validation and representativeness of the Spanish BIG-PAC database: integrated computerized medical records for research into epidemiology, medicines and health resource use (real world evidence)","volume":"22","author":"Sicras-Mainar","year":"2019","journal-title":"Value in Health."},{"key":"B21","unstructured":"2021"},{"key":"B22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.rec.2019.08.012","article-title":"Recommendations to improve lipid control Consensus document of the Spanish Society of Cardiology","volume":"73","author":"Escobar","year":"2020","journal-title":"Rev Esp Cardiol (Engl Ed)."},{"key":"B23","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol."},{"key":"B25","unstructured":"The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC\/DDD)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1001\/jama.288.4.455","article-title":"Long-term persistence in use of statin therapy in elderly patients","volume":"288","author":"Benner","year":"2002","journal-title":"JAMA"},{"key":"B27","unstructured":"2016"},{"key":"B28","unstructured":"Ganancia media laboral por edad y sexo"},{"key":"B29","unstructured":"BOT Plus 2Base de Datos de Medicamentos"},{"key":"B30","first-page":"6","article-title":"Prevalencia y grado de control de los factores de riesgo cardiovascular en pacientes con cardiopat\u00eda isqu\u00e9mica adscritos a un centro de salud urbano","volume":"95","author":"Alarc\u00f3n","year":"2021","journal-title":"Rev Esp Salud P\u00fablica."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e49","DOI":"10.1016\/j.atherosclerosissup.2021.01.009","article-title":"Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project","volume":"42","author":"Landmesser","year":"2020","journal-title":"Atheroscler Suppl."},{"key":"B32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.rccl.2019.10.001","article-title":"Individual trends in LDL-C control in patients with previous myocardial infarction","volume":"55","author":"R\u00f3denas","year":"2020","journal-title":"REC: CardioClinics."},{"key":"B33","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.ijcard.2019.05.071","article-title":"Number of drugs used in secondary cardiovascular prevention and late survival in the population of Valencia Community, Spain","volume":"293","author":"Red\u00f3n","year":"2019","journal-title":"Int J Cardiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.recesp.2019.10.013","article-title":"Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry","volume":"73","author":"P\u00e9rez","year":"2020","journal-title":"Rev Esp Cardiol (Engl Ed)."},{"key":"B35","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1097\/01.mlr.0000160417.39497.a9","article-title":"Accuracy of ICD-9-CM Codes for Identifying Cardiovascular and Stroke Risk Factors","volume":"43","author":"Birman-Deych","year":"2005","journal-title":"Med Care."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1161\/01.STR.29.8.1602","article-title":"Accuracy of ICD-9-CM coding for the identification of patients with acute ischemic stroke","volume":"29","author":"Goldstein","year":"1998","journal-title":"Stroke."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.966049\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T05:02:50Z","timestamp":1659589370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.966049\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":36,"alternative-id":["10.3389\/fcvm.2022.966049"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.966049","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,4]]},"article-number":"966049"}}